

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Levemir, Tresiba & Toujeo Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Levemir, Tresiba & Toujeo.** <u>Please complete all sections, incomplete forms will delay processing.</u> <u>Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104</u>. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

1 - Patient Information

KP-MAS Formulary can be found at: Pharmacy | Community Provider Portal | Kaiser Permanente

Patient Name:	Kaiser Medical ID#:	Date of Birth:		
2 – Prescriber Information				
Prescriber Name:	Specialty:	NPI:		
Prescriber Address:				
Prescriber Phone #:	Prescriber Fax #:			
3 – Pharmacy Information				
Pharmacy Name:	Pharmacy NPI:			
Pharmacy Phone #	Pharmacy Fax #:			
	4 – Drug Therapy Requested			
Drug 1: Name/Strength/Formulation:				
Drug 2: Name/Strength/Formulation:				
5– Diagnosis/Clinical Criteria				
Is this request for initial or continuing	ng therany?			
☐ Initial therapy	☐ Continuing therapy, State date:			
2. Indicate the patient's diagnosis for the requested medication:				

Clinical Criteria:			
	Member has an intolerance or failed an adequate trial of NPH AND insulin glargine-yfgn (unbranded Semglee), □ No □ Yes		
2.	AND prescribed for Type 1 Diabetes as basal insulin, □ No □ Yes		
3.	OR prescribed for member with Type 2 Diabetes who experiences recurrent nocturnal hypoglycemia (low blood sugar at night) with bedtime NPH insulin dosing defined as: ≥3 episodes of nocturnal capillary blood glucose (CBG) at night <70 mg/dL over the preceding 30 days, □ No □ Yes		
4.	OR prescribed for member with Type 2 Diabetes on NPH insulin that experiences any episode of severe hypoglycemia defined as: hypoglycemia resulting in seizures, loss of consciousness, episode necessitating assistance from someone else, and/or use of glucagon, □ No □ Yes		
5.	OR prescribed for member with Type 2 Diabetes that requires ultra-long-acting insulin due to work (i.e., night shift work where hours of sleep are significantly and repeatedly varied over time, frequent time-zone traveler) □ No □ Yes		
	loStar/Pen Criteria (must meet above criteria) PLUS: Unable to draw up insulin accurately from a vial with a syringe due to young age, visual impairment, physical disabilities (i.e., amputation, tremors/Parkinson's disease, rheumatoid arthritis), □ No □ Yes		
2.	OR requires small doses of insulin (<5 units per dose), □ No □ Yes		
3.	OR pediatric member who is required to use such a device by their school ☐ No ☐ Yes		
Eo	r continuation of therapy, please respond to <u>additional questions</u> below.		
	Adherence (>80%) to diabetic regimen, □ No □ Yes		
2.	AND member has documented A1C lowering of 0.5% from initial or A1C now at goal \Box No \Box Yes		
3.	AND must continue to meet inclusion criteria □ No □ Yes		
	6 – Prescriber Sign-Off		
no	ditional Information – Please submit chart notes/medical records for the patient that are applicable to this request. If to any of the above questions, please provide any additional supporting information that should be taken into nsideration:		

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	Date:
resember signature.	Butc.
Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is	

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility